How To Bleed Air From Sprinkler System

European Union: the approved anti-obesity drug Acomplia

Sanofi Aventis announced that the European Commission has approved the marketing of anti-obesity drug Acomplia (active ingredient: rimonabant). E 'approved, the dose of 20mg. The first launch of the drug is expected in Britain in July. You will then be introduced in Denmark, Ireland, Germany, Finland and Norway, during the second half of 2006. Acomplia is indicated in obese patients (body mass index, BMI, greater than or equal to 30kg/m2) or overweight patients (BMI> 24kg/m2) with associated risk factors (diabetes type 2, dyslipidemia).

Do-scorpio-men-develop-feelings-for.html

Migraine: attack frequency and severity of conditions are related to body mass index

Researchers at Albert Einstein College of Medicine in New York have made a survey to analyze the influence of body mass index (BMI, body mass index) on the prevalence, attack frequency and clinical features migraine. The study population was based on telephone interviews that allowed to obtain information about the headache, the height and weight of 30,215 participants. The enrolled subjects were divided into five categories according to their BMI: underweight (BMI < or =" 1.3" or =" 2.9" or =" 5.7" or =" 1.9">

ME Bigal et al, Neurology 2006, 66: 545-550

Dental Hygiene New Grad Sample Cover Letter

The effect of homeopathic treatment on mental symptoms of patients with generalized anxiety disorder did not differ from placebo

Researchers at the Department of Psychiatry at Hadassah University in Jerusalem in Israel have assessed the 'effect of homeopathic treatment in generalized anxiety disorder. A total of 44 patients with generalized anxiety disorder according to DSM-IV were randomly assigned to receive for 10 weeks a homeopathic remedy, individualized, or placebo. 39 patients completed the study. E 'was observed a significant improvement in Most rating scales, including the HAM-A (Hamilton Rating Scale for Anxiety) and the group treated with the homeopathic remedy that with placebo.

Bonne O et al, J Clin Psychiatry 2003; 64: 282-287

Specialized Frames Are Made

Implications of cannabinoids in diseases neurological

Preparations of Cannabis sativa (marijuana) are used for many centuries both for medical purposes and for recreational use. Recent advances in understanding of the pharmacological properties especially of delta9-tetrahydrocannabinol (Delta9-THC) and the physiological roles of endocannabinoids led to the development of new strategies in the treatment of psychiatric disorders and neurological ones. Potential uses of cannabinoid receptor antagonists include the management of spasticity and tremor in multiple sclerosis and spinal injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer and vasodilation associated with the advanced form cirrhosis. Of CB1 receptor antagonists have, however, therapeutic potential in Parkinson's disease.

Alsasua Del Valle A, Cell Mol Neurobiol 2006

Information Of Bertazzoni Sto

A gene Reverte Parkinson's disease in an animal model

aggregates of alpha-synuclein are characteristic of Parkinson's disease. Researchers at the Whitehead Institute in Cambridge (USA) evaluated whether to prevent the formation of these aggregates corresponded less neuronal death. In collaboration with the University of Missouri (USA), researchers have shown that a mutated form of alpha-synuclein destroyed a transport protein causing the death of neurons. Researchers have identified a gene that increases the production of the transport protein. In animal models it was observed that the gene is able to revert the symptoms of Parkinson's disease.

Fonte: Science, 2006